Ken Griffin Cyclo Therapeutics, Inc. Transaction History

Citadel Advisors LLC

  • $505 Billion
  • Q3 2024

Shares

5 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 14, 2024
BUY
$1.16 - $1.53 $28,617 - $37,745
24,670 New
24,670 $31,000
Q4 2023

Feb 14, 2024
BUY
$0.93 - $1.88 $37,089 - $74,976
39,881 Added 282.1%
54,018 $85,000
Q3 2023

Nov 14, 2023
SELL
$1.26 - $1.88 $3,580 - $5,342
-2,842 Reduced 16.74%
14,137 $20,000
Q2 2023

Aug 14, 2023
SELL
$0.67 - $2.3 $1,019 - $3,500
-1,522 Reduced 8.23%
16,979 $26,000
Q1 2023

May 15, 2023
BUY
$0.82 - $2.27 $15,170 - $41,997
18,501 New
18,501 $15,000

Others Institutions Holding CYTH

# of Institutions
20
Shares Held
2.25M
Call Options Held
0
Put Options Held
0
View Full List

About Cyclo Therapeutics, Inc.

CYTH Quotes by TradingView
  • Ticker CYTH
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Drug Manufacturers—Specialty & Generic
  • Shares Outstandng 8,439,440
  • Market Cap $6.16M
  • Description
  • Cyclo Therapeutics, Inc., a clinical stage biotechnology company, develops cyclodextrin-based products for the treatment of various diseases. Its lead drug candidate is Trappsol Cyclo, an orphan drug, which is Phase III clinical trials for the treatment of Niemann-Pick Type C disease. The company also develops Trappsol Cyclo for the treatment of...
More about CYTH
Track Ken Griffin's Portfolio

Track Ken Griffin Portfolio

Follow Ken Griffin (Citadel Advisors LLC) and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Citadel Advisors LLC, based on Form 13F filings with the SEC.

News

Stay updated on Citadel Advisors LLC and Ken Griffin with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email